Veracyte (VCYT) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- S&P 500 ends higher as traders shift from AI to healthcare
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
- Vertiv shares fall on analyst downgrades and options bets
- S&P 500 ends higher as traders shift from AI to healthcare
- Rocket Lab USA (RKLB) Reiterated at Overweight by Cantor Fitzgerald as Neutron Launch Moved to Next Year
- Caterpillar names Derrick York to lead Resource Industries
- Intel shares drop on foundry risks, sector pressures
Veracyte Announces Third Quarter 2017 Financial Results
November 6, 2017 4:05 PM EST
Reports Revenue of $17.5 Million for the Third Quarter 2017
Highlights
Business Progress
Conference Call and Webcast Today at 4:30
p.m. ET
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ: VCYT) today announced financial results for the third quarter ended September 30, 2017 and provided an update on recent business progress. For the third quarter of 2017, revenue was $17.5 million, compared to $18.6 million for the third quarter of 2016. Excluding the impact of cash collections for tests performed prior to July 1, 2016, accrued revenue increased 24%. Genomic test volume was... More



